SG11201909678PA - Process for the manufacture of vortioxetine hbr alpha-form - Google Patents
Process for the manufacture of vortioxetine hbr alpha-formInfo
- Publication number
- SG11201909678PA SG11201909678PA SG11201909678PA SG11201909678PA SG 11201909678P A SG11201909678P A SG 11201909678PA SG 11201909678P A SG11201909678P A SG 11201909678PA SG 11201909678P A SG11201909678P A SG 11201909678PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- manufacture
- vortioxetine hbr
- alpha
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- VNGRUFUIHGGOOM-UHFFFAOYSA-N vortioxetine hydrobromide Chemical compound Br.CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 VNGRUFUIHGGOOM-UHFFFAOYSA-N 0.000 title abstract 3
- OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700264 | 2017-04-25 | ||
PCT/EP2018/060192 WO2018197360A1 (en) | 2017-04-25 | 2018-04-20 | Process for the manufacture of vortioxetine hbr alpha-form |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909678PA true SG11201909678PA (en) | 2019-11-28 |
Family
ID=62111030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909678P SG11201909678PA (en) | 2017-04-25 | 2018-04-20 | Process for the manufacture of vortioxetine hbr alpha-form |
Country Status (26)
Country | Link |
---|---|
US (1) | US11124491B2 (ja) |
EP (1) | EP3615518B1 (ja) |
JP (1) | JP7121751B2 (ja) |
KR (1) | KR102551433B1 (ja) |
CN (1) | CN110520415A (ja) |
AU (1) | AU2018258947C1 (ja) |
BR (1) | BR112018076411A2 (ja) |
CA (1) | CA3059515A1 (ja) |
CL (1) | CL2019003024A1 (ja) |
CO (1) | CO2019011592A2 (ja) |
CY (1) | CY1124974T1 (ja) |
DK (1) | DK3615518T3 (ja) |
ES (1) | ES2905962T3 (ja) |
HR (1) | HRP20220108T1 (ja) |
HU (1) | HUE057993T2 (ja) |
IL (1) | IL270052B2 (ja) |
LT (1) | LT3615518T (ja) |
MA (1) | MA49056A (ja) |
MX (1) | MX2019012765A (ja) |
PL (1) | PL3615518T3 (ja) |
PT (1) | PT3615518T (ja) |
RS (1) | RS62823B1 (ja) |
SG (1) | SG11201909678PA (ja) |
SI (1) | SI3615518T1 (ja) |
WO (1) | WO2018197360A1 (ja) |
ZA (1) | ZA201906829B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210087155A1 (en) * | 2018-02-06 | 2021-03-25 | Piramal Enterprises Limited | An improved process for the preparation of vortioxetine and salts thereof |
CN112125868B (zh) * | 2020-09-25 | 2021-08-03 | 中山万远新药研发有限公司 | 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
MX2008016141A (es) * | 2006-06-16 | 2009-02-04 | Lundbeck & Co As H | 1-[2-(2,4-dimetilfenilsulfanil)-fenil] piperazina como un compuesto con actividad combinada de recaptación de serotonina, 5-ht3 y 5-ht1a.para el tratamiento de daño cognitivo. |
TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
TW201033181A (en) * | 2009-02-17 | 2010-09-16 | Lundbeck & Co As H | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
EP2897943B1 (en) | 2012-09-19 | 2019-04-24 | Sandoz AG | Crystalline form of vortioxetine hydrobromide |
WO2015114395A1 (en) * | 2014-01-31 | 2015-08-06 | Egis Gyógyszergyár Zrt. | Process for the preparation of vortioxetine salts |
US9687484B2 (en) | 2014-07-18 | 2017-06-27 | Dipharma Francis S.R.L. | Crystalline forms of an antidepressant compound |
CN105367515B (zh) | 2015-05-08 | 2017-10-27 | 北京北陆药业股份有限公司 | 一种氢溴酸沃替西汀α晶型的制备方法 |
CN104910099B (zh) | 2015-05-22 | 2017-03-08 | 扬子江药业集团有限公司 | 一种氢溴酸沃替西汀晶体的制备方法 |
CN106316986B (zh) | 2015-07-03 | 2019-02-05 | 成都弘达药业有限公司 | 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪氢溴酸盐α型晶体的制备方法 |
-
2018
- 2018-04-20 PT PT187219753T patent/PT3615518T/pt unknown
- 2018-04-20 SI SI201830537T patent/SI3615518T1/sl unknown
- 2018-04-20 LT LTEPPCT/EP2018/060192T patent/LT3615518T/lt unknown
- 2018-04-20 AU AU2018258947A patent/AU2018258947C1/en active Active
- 2018-04-20 IL IL270052A patent/IL270052B2/en unknown
- 2018-04-20 BR BR112018076411-6A patent/BR112018076411A2/pt unknown
- 2018-04-20 HU HUE18721975A patent/HUE057993T2/hu unknown
- 2018-04-20 PL PL18721975T patent/PL3615518T3/pl unknown
- 2018-04-20 SG SG11201909678P patent/SG11201909678PA/en unknown
- 2018-04-20 CA CA3059515A patent/CA3059515A1/en active Pending
- 2018-04-20 KR KR1020197031292A patent/KR102551433B1/ko active IP Right Grant
- 2018-04-20 JP JP2019557745A patent/JP7121751B2/ja active Active
- 2018-04-20 EP EP18721975.3A patent/EP3615518B1/en active Active
- 2018-04-20 RS RS20220047A patent/RS62823B1/sr unknown
- 2018-04-20 WO PCT/EP2018/060192 patent/WO2018197360A1/en unknown
- 2018-04-20 HR HRP20220108TT patent/HRP20220108T1/hr unknown
- 2018-04-20 US US16/604,313 patent/US11124491B2/en active Active
- 2018-04-20 ES ES18721975T patent/ES2905962T3/es active Active
- 2018-04-20 MX MX2019012765A patent/MX2019012765A/es unknown
- 2018-04-20 CN CN201880025179.2A patent/CN110520415A/zh active Pending
- 2018-04-20 MA MA049056A patent/MA49056A/fr unknown
- 2018-04-20 DK DK18721975.3T patent/DK3615518T3/da active
-
2019
- 2019-10-16 ZA ZA2019/06829A patent/ZA201906829B/en unknown
- 2019-10-18 CO CO2019011592A patent/CO2019011592A2/es unknown
- 2019-10-22 CL CL2019003024A patent/CL2019003024A1/es unknown
-
2022
- 2022-02-08 CY CY20221100108T patent/CY1124974T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201808476SA (en) | Recycling of polymer matrix composite | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201810611YA (en) | Coumarin compounds and their uses as fluorescent labels | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
SG11201901873PA (en) | Tablet compositions | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201901172QA (en) | A method for manufacturing a fuel component | |
SG11201805191SA (en) | Yeast cell | |
SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
SG11201808992UA (en) | Compositions and methods for the detection of host cell proteins |